What are the safe usage guidelines and potential side effects of progesterone (a steroid hormone) therapy in pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Progesterone Side Effects in Pregnancy

Progesterone therapy in pregnancy has an excellent safety profile with no significant long-term adverse effects on children or increased risk of major congenital anomalies, though maternal side effects like drowsiness, dizziness, and headaches are common. 1, 2

Safety Profile for the Fetus

Long-term follow-up studies demonstrate no developmental concerns:

  • Children exposed to progesterone in utero showed no differences in physical examination, health status, or developmental performance (motor, problem-solving, personal-social skills) at 4-year follow-up compared to placebo 1
  • Multiple studies have failed to detect long-term adverse effects from intrauterine progesterone exposure, even when administered in the first trimester 1

Important caveat regarding congenital anomalies:

  • The FDA drug label lists rare cases of cleft palate, cleft lip, hypospadias, ventricular septal defect, patent ductus arteriosus, and other congenital heart defects 2
  • However, these represent isolated case reports without established causal relationship, and the overall evidence base shows no increased risk in controlled trials 1

Common Maternal Side Effects

Frequent but generally mild side effects include: 2

  • Drowsiness and dizziness (most common, particularly with oral formulations)
  • Headaches
  • Breast pain or tenderness
  • Irregular vaginal bleeding or spotting
  • Stomach or abdominal cramps and bloating
  • Nausea and vomiting
  • Fluid retention
  • Vaginal yeast infection
  • Hair loss

Critical safety warning for oral progesterone: 2

  • Some women experience extreme dizziness and/or drowsiness during initial therapy
  • In rare cases, symptoms may include blurred vision, difficulty speaking, difficulty walking, and feeling abnormal
  • Patients should take oral progesterone at bedtime while standing with a full glass of water
  • Caution is required when driving or operating machinery

Serious but Rare Side Effects

Thromboembolic events (very rare): 2

  • Stroke
  • Heart attack
  • Pulmonary embolus
  • Visual loss or blindness

Warning signs requiring immediate medical attention: 2

  • Changes in vision or speech
  • Sudden new severe headaches
  • Severe chest or leg pain with or without shortness of breath
  • Weakness and fatigue
  • Dizziness and faintness
  • Vomiting

Route-Specific Considerations

Vaginal progesterone (90-mg gel or 200-mg suppository):

  • Generally better tolerated than oral formulations 1
  • Lower systemic side effects due to first-uterine-pass effect
  • Local side effects may include vaginal discharge or irritation

Intramuscular 17-hydroxyprogesterone caproate (17P):

  • Injection site reactions possible 1
  • Systemic side effects similar to other formulations but may be less pronounced than oral

Oral micronized progesterone:

  • Highest incidence of drowsiness and dizziness 2
  • Must be taken at bedtime to minimize impact on daily activities

Contraindications and Precautions

Allergy warning: 2

  • Progesterone capsules contain peanut oil
  • Contraindicated in patients with peanut allergy

Risk factors requiring closer monitoring: 2

  • History of thromboembolic disease
  • High blood pressure
  • High cholesterol
  • Diabetes
  • Obesity
  • Tobacco use

Clinical Context for Safety

The safety profile supports use in appropriate clinical scenarios:

  • Progesterone is recommended for singleton pregnancies with prior preterm birth (17P 250 mg IM weekly from 16-20 weeks until 36 weeks) 1
  • Vaginal progesterone is recommended for singleton pregnancies with short cervical length ≤20 mm at 18-24 weeks 1
  • Not recommended for multiple gestations, active preterm labor, or preterm premature rupture of membranes, as efficacy has not been demonstrated in these populations 1

Key pitfall to avoid:

The evidence for progesterone safety comes primarily from its use in preterm birth prevention protocols. Extrapolating safety data to other uses (such as threatened miscarriage in women without prior losses) requires caution, as the risk-benefit profile may differ 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT.

Health technology assessment (Winchester, England), 2020

Research

"Natural" progesterone: information on fetal effects.

Birth defects research. Part B, Developmental and reproductive toxicology, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.